Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 35 to 44 Women only

Dydrogesterone versus GnRH antagonist for women with low ovarian response using double ovarian stimulation

Official title: Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial

Run by Bedaya Hospital · NCT06212102 · Data updated 2026-11-12

This trial will test whether dydrogesterone or a GnRH antagonist better prevents a premature LH surge and improves outcomes and costs for women with poor ovarian response undergoing double ovarian stimulation for IVF.

More Infertility trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages35 Years to 44 Years
SexWomen only
Enrollment120 (estimated)
SponsorBedaya Hospital
Academic / other
Locations2 sites (Cairo, Cairo Governorate and 1 other locations)
StatusRecruiting
StartedMay 8, 2024
Main results expectedMarch 1, 2027
Study endsAugust 1, 2027
Registry record updatedMay 4, 2026
Trial IDNCT06212102 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Women with infertility classified as POSEIDON group 4 who are planning double ovarian stimulation as part of IVF and who do not have PCOS, endometriosis, or a history of recurrent miscarriage.

Probably not a fit

Women with PCOS, endometriosis, recurrent abortion, or those not classified as POSEIDON group 4 or not undergoing double stimulation are unlikely to benefit from this comparison.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This phase II randomized trial assigns women in POSEIDON group 4 to either progestin-primed ovarian stimulation with dydrogesterone or a standard GnRH antagonist protocol during double ovarian stimulation. The primary focus is prevention of premature LH surge, with secondary outcomes including ovarian response, embryo yield, and cost-effectiveness. Key exclusions are PCOS, endometriosis, and a history of recurrent abortion. The trial is conducted at Cairo University and Bedaya Hospital in the Cairo/Giza region.

Why it matters

Potential benefit: If successful, this could provide a simpler and potentially lower-cost method to prevent premature LH surge and increase usable embryos for women who respond poorly to stimulation.

How similar studies have gone: Progestin-primed ovarian stimulation and GnRH antagonist protocols have each been used successfully in other IVF settings, but randomized head-to-head data specifically in POSEIDON group 4 patients undergoing double stimulation are limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Patients belonging to Poseidon group 4

Exclusion Criteria:

* PCOS
* Endometriosis
* History of recurrent abortion

Where it's running

  • Cairo University
    Cairo, Cairo Governorate, Egypt
    Recruiting
  • Bedaya Hospital
    Giza, Egypt
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Browse more
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.